Article PDF
Avoid common mistakes on your manuscript.
References
Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202–2211.
Finklestein JZ, Gilchrist GS. Recent advances in neuroblastoma. Calif Med 1972;116:27–36.
Moreno L, Marshall LV, Pearson AD. At the frontier of progress for paediatric oncology: the neuroblastoma paradigm. Br Med Bull 2013;108:173–188.
Kagedal B. Detecting minimal residual disease in neuroblastoma: still a ways to go. Clin Chem 2009;55:1268–1270.
Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106–2120.
Lee AC. Neuroblastoma: the challenge remains. Singapore Med J 2012;53:1–2.
Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010;24:65–86.
Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, et al. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2013;60:985–993.
Oberthuer A. Genomic markers for neuroblastoma risk estimation: superseding tumor stage, age and MYCN? Biomark Med 2013;7:905–908.
Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, Pistoia V, et al. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front Immunol 2014;5:56.
Bourdeaut F, Trochet D, Janoueix-Lerosey I, Ribeiro A, Deville A, Coz C, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Cancer Lett 2005;228:51–58.
Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26:682–694.
Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013;45:279–284.
Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13:397–411.
Pichler M, Calin GA. Long noncoding RNA in neuroblastoma: new light on the (old) N-Myc story. J Natl Cancer Inst 2014;106. doi: 10.1093/jnci/dju150.
Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 2008;27:441–449.
Vermeulen J, De Preter K, Mestdagh P, Laureys G, Speleman F, Vandesompele J. Predicting outcomes for children with neuroblastoma. Discov Med 2010;10:29–36.
Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012;483:589–593.
Mei H, Lin ZY, Tong QS. The roles of microRNAs in neuroblastoma. World J Pediatr 2014;10:10–16.
Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, et al. The miR-17–92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 2010;40:762–773.
Chen Y, Tsai YH, Fang Y, Tseng SH. Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. J Pediatr Surg 2012;47:1797–1805.
Yu M, Ohira M, Li Y, Niizuma H, Oo ML, Zhu Y, et al. High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol 2009;34:931–938.
Pandey GK, Mitra S, Subhash S, Hertwig F, Kanduri M, Mishra K, et al. The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Cancer Cell 2014;26:722–737.
Vance KW, Sansom SN, Lee S, Chalei V, Kong L, Cooper SE, et al. The long non-coding RNA Paupar regulates the expression of both local and distal genes. EMBO J 2014;33:296–311.
Zhao X, Li D, Pu J, Mei H, Yang D, Xiang X, et al. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression. Oncogene 2015. doi: 10.1038/onc.2015.422.
Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, et al. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression. J Natl Cancer Inst 2014;106. doi: 10.1093/jnci/dju113.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mei, H., Lin, ZY. & Tong, QS. Risk stratification and therapeutics of neuroblastoma: the challenges remain. World J Pediatr 12, 5–7 (2016). https://doi.org/10.1007/s12519-016-0001-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-016-0001-6